A Solution for Non-Healing Diabetic Foot Ulcers
We are thrilled to announce the launch of DIAQUIL, a pioneering product specifically formulated to treat Non-Healing Diabetic Foot Ulcers (NHDFU). At Hetero Healthcare, our unwavering commitment is to improve the lives of those suffering from diabetic foot complications by offering innovative treatments that can prevent limb amputation and enhance the quality of life.
DIAQUIL represents a major leap forward in the management of Diabetic Foot Ulcers. This cutting-edge product features a patented formulation that uniquely targets and regulates Metallo Proteinase activity to prevent the breakdown of the extracellular matrix. By doing so, DIAQUIL not only accelerates the healing process but also promotes tissue regeneration, offering renewed hope for patients who have long battled with these challenging and often debilitating ulcers.
Changing the Narrative for NHDFU Patients
Our goal with DIAQUIL is to shift the paradigm of NHDFU treatment. We aim to reduce the need for amputations and empower patients to reclaim their health and independence. DIAQUIL provides a promising new option for those whose lives have been significantly affected by diabetic foot ulcers, offering a chance for healing and a better quality of life.
Join Us in Our Mission to Transform Patient Care
We invite healthcare professionals, caregivers, and stakeholders to join us in this vital mission. Together, we can make a substantial difference in the lives of patients with diabetic foot ulcers, improving outcomes and delivering hope.
For more information about DIAQUIL and how you can partner with us to enhance patient care, please visit our website or contact us directly.
About Hetero Healthcare
Hetero Healthcare is dedicated to providing innovative, high-quality healthcare solutions to patients worldwide. Our focus is on delivering groundbreaking treatments that address the most pressing health challenges, helping patients lead healthier, more fulfilling lives.
For more pictures, visit our social media pages :
ILCC 2024 was the third National conference of STII organised by ILBS. It was held on September 28th and 29th, 2024, at The Grand New Delhi.
Our Gastrocare Team of Hetero Healthcare held a Managers Development Program (MDP) in Mumbai from 12th to 14th September 2024 to enhance the Skills and Knowledge of Managers needed to lead effectively and drive organisational success.
In September, an impactful nationwide campaign titled "Golden Cape Hero" was executed by Hetero Healthcare’s Oncology Division across 33 hospitals in India to raise awareness about childhood cancer.
Big shoutout to our amazing performers of FY 2022-23! Management has recognized their hard work and dedication by awarding them two-wheelers. Congratulations to all the winners.
On June 5th, our team came together with our core customers to celebrate World Environment Day. We marked the occasion by presenting plants to our clients, reinforcing our commitment to a greener planet.
We recently launched our prestigious TNKPLASE (Tenecteplase 40mg Injection). The team showed their enthusiasm by wearing TNKPLASE t-shirts, making the event even more special.
This Doctors' Day, the Volga Division of Hetero Healthcare Limited took an innovative approach to show their appreciation for the medical community.
Exciting news! Volga Division proudly unveils 'HETROSE', a breakthrough brand combating iron deficiency anaemia.
The Oncology Division of Hetero Healthcare conducted Rayfetox activity at Deenanath Mangeshkar Hospital, Pune, with Dr Shailesh Kanvinde, Pediatric Hematologist.
The Telangana team received Blazers from our beloved Director Mr. Namburi Bose and Assoc.
Your email address & phone will not be published. Required fields are marked *
Copyright ©2024 All Rights Reserved by Hetero Healthcare Limited.